Search - tctmd.com

Displaying 1 - 20 of 45

Sort: Relevancy | Date

US Obesity Epidemic Continues to Skyrocket, With No End in Sight

News Conference News AHA 2024

US Obesity Epidemic Continues to Skyrocket, With No End in Sight

Michael O'Riordan

November 15, 2024

Most HFrEF Patients Eligible for Quadruple Therapy, but Few Get It

News Conference News ACC 2024

Most HFrEF Patients Eligible for Quadruple Therapy, but Few Get It

Michael O'Riordan

March 27, 2024

High LDL, Poor Treatment, Early Death: HoFH Registry Paints Grim Picture

News Conference News EAS 2023

High LDL, Poor Treatment, Early Death: HoFH Registry Paints Grim Picture

Michael O'Riordan

May 23, 2023

FH Patients Face Unchanging Acute MI Risks Plus Very Late Diagnoses

News Conference News EAS 2022

FH Patients Face Unchanging Acute MI Risks Plus Very Late Diagnoses

Michael O'Riordan

May 26, 2022

Stepwise or Hammer Down? Experts Debate Best Approach to LDL-Lowering

News Conference News EAS 2022

Stepwise or Hammer Down? Experts Debate Best Approach to LDL-Lowering

Michael O'Riordan

May 24, 2022

Registry Data Hint at MACE Benefit with Renal Denervation

News Conference News EuroPCR 2022

Registry Data Hint at MACE Benefit With Renal Denervation

Michael O'Riordan

May 17, 2022

Failed MitraClip Is Uncommon, but Bleak When It Happens

News Conference News TCT 2021

Failed MitraClip Is Uncommon, but Bleak When It Happens

Michael O'Riordan

October 08, 2021

High- and Low-Dose Aspirin Equivalent in ASCVD: ADAPTABLE

News Conference News ACC 2021

High- and Low-Dose Aspirin Equivalent in ASCVD: ADAPTABLE

Michael O'Riordan

May 15, 2021

EMBRACE HF: Empagliflozin Cuts PA Pressure in HF With or Without Diabetes

News Conference News HFSA 2020

EMBRACE HF: Empagliflozin Cuts PA Pressure in HF With or Without Diabetes

October 09, 2020

Low Mortality Rates Seen With Andexanet Alfa for Factor Xa-Related Bleeds

News Conference News ACC 2020

Low Mortality Rates Seen With Andexanet Alfa for Factor Xa-Related Bleeds

March 25, 2020

Updated EAS/ESC Dyslipidemia Guidelines Lower LDL Targets, Broaden Risk Categories

News Conference News ESC 2019

Updated EAS/ESC Dyslipidemia Guidelines Lower LDL Targets, Broaden Risk Categories

Yael L. Maxwell

September 06, 2019

New PURE Insights: CVD Deaths Dip in Rich Nations Amid Risk-Factor Surprises

News Conference News ESC 2019

New PURE Insights: CVD Deaths Dip in Rich Nations Amid Risk-Factor Surprises

Michael O'Riordan

September 04, 2019

Absence of FH Diagnosis Linked to Increased Risk of Premature Mortality

News Conference News EAS 2019

Absence of FH Diagnosis Linked to Increased Risk of Premature Mortality

Michael O'Riordan

June 05, 2019

CHD Mortality Significantly Elevated in Patients With Severe FH

News Conference News EAS 2019

CHD Mortality Significantly Elevated in Patients With Severe FH

Michael O'Riordan

May 29, 2019

Off-Label Underdosing of DOACs Tied to Worse Outcomes in A-fib Patients

News Conference News ISC 2019

Off-Label Underdosing of DOACs Tied to Worse Outcomes in A-fib Patients

February 07, 2019

Pretreatment With P2Y12 Inhibitors Questioned Anew in SCAAR

News Conference News ESC 2018

Pretreatment With P2Y12 Inhibitors Questioned Anew in SCAAR

August 28, 2018

ASCEND: Aspirin Doesn’t Look Good for Primary CV Prevention in Diabetic Patients

News Conference News ESC 2018

ASCEND: Aspirin Doesn’t Look Good for Primary CV Prevention in Diabetic Patients

August 26, 2018

Aspirin Fails to Prevent CV Events in People at ‘Moderate’ Risk of Disease: ARRIVE

News Conference News ESC 2018

Aspirin Fails to Prevent CV Events in People at ‘Moderate’ Risk of Disease: ARRIVE

August 26, 2018

High CRP Linked to Bigger Absolute Drops in CV Events for Patients Taking Evolocumab

News Conference News ACC 2018

High CRP Linked to Bigger Absolute Drops in CV Events for Patients Taking Evolocumab

Michael O'Riordan

March 20, 2018

Precision Medicine Gamble Fails for CETP Inhibitors in ACCELERATE Analysis

News Conference News ACC 2018

Precision Medicine Gamble Fails for CETP Inhibitors in ACCELERATE Analysis

Michael O'Riordan

March 14, 2018

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.